Vertex Pharmaceuticals stock pre-market at EUR 446.85: plus 0.17 percent
Published on 10/07/2026 at 08:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals stock was at EUR 446.85 in pre-market trading at 8:09 a.m. CEST on October 7, 2026, according to Lang & Schwarz. The price was up EUR 0.75, or 0.17 percent, versus the Lang & Schwarz prior close of EUR 446.10 on October 6, 2026.
Pre-market price
Vertex Pharmaceuticals stock was quoted at EUR 446.85 before the Xetra open, compared with the prior Lang & Schwarz close of EUR 446.10 on October 6, 2026. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Vertex Pharmaceuticals stock.
Previous company development
In a September 22, 2026, release, Vertex Pharmaceuticals said its Phase 2b AMPLIFIED study of inaxaplin produced a 42.7 percent reduction in urine albumin-to-creatinine ratio at Week 13 from baseline among participants with APOL1-mediated kidney disease and modest proteinuria. The company also said enrollment in the Phase 2/3 AMPLITUDE trial was complete.
